PMID- 32854858
OWN - NLM
STAT- MEDLINE
DCOM- 20211011
LR  - 20211011
IS  - 2162-5514 (Electronic)
IS  - 0074-7742 (Linking)
VI  - 155
DP  - 2020
TI  - Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, 
      metformin, and thiazolidinediones.
PG  - 37-64
LID - S0074-7742(20)30019-2 [pii]
LID - 10.1016/bs.irn.2020.02.010 [doi]
AB  - Medical and scientific communities have been striving to disentangle the 
      complexity of neurodegenerative diseases, particularly Alzheimer's disease (AD) 
      and Parkinson's disease (PD), in order to develop a cure or effective treatment 
      for these diseases. Along this journey, it has become important to identify the 
      early events occurring in the prodromal phases of these diseases and the 
      disorders that increase the risk of neurodegeneration highlighting common 
      pathological features. This strategy has led to a wealth of evidence identifying 
      diabetes, mainly type 2 diabetes mellitus (T2DM) as a main risk factor for the 
      onset and progression of AD and PD. Impaired glucose metabolism, insulin 
      resistance, and mitochondrial dysfunction are features common to both type 2 
      diabetes mellitus (T2DM), and AD and PD, and they appear before clinical 
      diagnosis of the two neurodegenerative diseases. These could represent the 
      strategic nodes of therapeutic intervention. Following this line of thought, a 
      conceivable approach is to repurpose antidiabetic drugs as valuable agents that 
      may prevent or reduce the risk of cognitive decline and neurodegeneration. This 
      review summarizes the past and current findings that link AD and PD with T2DM, 
      emphasizing the common pathological mechanisms. The efficacy of antidiabetic 
      drugs, namely intranasal insulin, metformin, and thiazolidinediones, in the 
      prevention and/or treatment of AD and PD is also discussed.
CI  - (c) 2020 Elsevier Inc. All rights reserved.
FAU - Cardoso, Susana
AU  - Cardoso S
AD  - CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 
      Portugal; CIBB-Center for Innovative Biomedicine and Biotechnology, University of 
      Coimbra, Coimbra, Portugal; IIIUC-Institute of Interdisciplinary Research, 
      University of Coimbra, Coimbra, Portugal. Electronic address: 
      susana.t.cardoso@gmail.com.
FAU - Moreira, Paula I
AU  - Moreira PI
AD  - CNC-Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, 
      Portugal; CIBB-Center for Innovative Biomedicine and Biotechnology, University of 
      Coimbra, Coimbra, Portugal; Laboratory of Physiology-Faculty of Medicine, 
      University of Coimbra, Coimbra, Portugal. Electronic address: venta@ci.uc.pt.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200811
PL  - United States
TA  - Int Rev Neurobiol
JT  - International review of neurobiology
JID - 0374740
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 0 (Thiazolidinediones)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Alzheimer Disease/*drug therapy
MH  - Diabetes Mellitus, Type 2/drug therapy
MH  - *Drug Repositioning
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin/*therapeutic use
MH  - Metformin/*therapeutic use
MH  - Parkinson Disease/*drug therapy
MH  - Thiazolidinediones/*therapeutic use
OTO - NOTNLM
OT  - Alzheimer's disease
OT  - Antidiabetic drugs
OT  - Cerebral glucose metabolism
OT  - Diabetes
OT  - Insulin resistance
OT  - Mitochondrial (dys)function
OT  - Parkinson's disease
EDAT- 2020/08/29 06:00
MHDA- 2021/10/12 06:00
CRDT- 2020/08/29 06:00
PHST- 2020/08/29 06:00 [entrez]
PHST- 2020/08/29 06:00 [pubmed]
PHST- 2021/10/12 06:00 [medline]
AID - S0074-7742(20)30019-2 [pii]
AID - 10.1016/bs.irn.2020.02.010 [doi]
PST - ppublish
SO  - Int Rev Neurobiol. 2020;155:37-64. doi: 10.1016/bs.irn.2020.02.010. Epub 2020 Aug 
      11.